The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC.
 
Johann Sebastian De Bono
Research Funding - Innocrin Pharma (Inst)
 
Carmel Jo Pezaro
Research Funding - Innocrin Pharma (Inst)
 
Silke Gillessen
Research Funding - Innocrin Pharma (Inst)
 
Neal D. Shore
Research Funding - Innocrin Pharma (Inst)
 
Luke T. Nordquist
No Relationships to Disclose
 
Eleni Efstathiou
Research Funding - Innocrin Pharma (Inst)
 
John C. Araujo
Research Funding - Innocrin Pharma (Inst)
 
William R. Berry
Research Funding - Innocrin Pharma (Inst)
 
Glenn Liu
Research Funding - Innocrin Pharma (Inst)
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Endocyte; Mannkind; UpToDate
Consulting or Advisory Role - Amgen; AVEO; BIND Biosciences; Janssen Biotech
Speakers' Bureau - Bayer; Caris MPI; Dendreon; GlaxoSmithKline; Medivation; Millennium; Sanofi
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology
 
Aurelius Gabriel Omlin
Research Funding - Innocrin Pharma (Inst)
 
Robert J. Schotzinger
Employment - Innocrin Pharma
Leadership - Innocrin Pharma
Stock and Other Ownership Interests - Innocrin Pharma
Patents, Royalties, Other Intellectual Property - Innocrin Pharmaceuticals, Inc.
 
Joel Robert Eisner
Employment - Innocrin Pharma
Stock and Other Ownership Interests - Innocrin Pharma
 
William R. Moore
Employment - Innocrin Pharma
Leadership - Innocrin Pharma
Stock and Other Ownership Interests - Innocrin Pharma